GeoVax Labs Inc. (NASDAQ:GOVX – Get Free Report) was the recipient of a significant increase in short interest in May. As of May 15th, there was short interest totaling 470,940 shares, an increase of 85.2% from the April 30th total of 254,323 shares. Currently, 13.6% of the shares of the company are short sold. Based on an average daily volume of 835,393 shares, the days-to-cover ratio is currently 0.6 days.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Sabby Management LLC purchased a new position in shares of GeoVax Labs in the 3rd quarter valued at $313,000. Renaissance Technologies LLC bought a new position in GeoVax Labs in the fourth quarter worth about $104,000. Jane Street Group LLC bought a new position in GeoVax Labs in the fourth quarter worth about $99,000. Armistice Capital LLC bought a new position in GeoVax Labs in the third quarter worth about $253,000. Finally, HRT Financial LP bought a new position in GeoVax Labs in the fourth quarter worth about $31,000. 6.09% of the stock is currently owned by hedge funds and other institutional investors.
GeoVax Labs Trading Up 7.3%
Shares of GeoVax Labs stock opened at $2.21 on Tuesday. The stock has a 50 day moving average of $1.61 and a 200 day moving average of $3.81. GeoVax Labs has a 12 month low of $0.96 and a 12 month high of $34.75. The firm has a market cap of $7.68 million, a PE ratio of -0.12 and a beta of 3.36.
Analysts Set New Price Targets
A number of research firms recently commented on GOVX. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Tuesday, April 21st. D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a research report on Thursday, April 16th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $150.00.
Check Out Our Latest Research Report on GeoVax Labs
GeoVax Labs Company Profile
GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.
The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.
Featured Articles
- Five stocks we like better than GeoVax Labs
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.
